{"entity":{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","aka":[],"tldr":"Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated.","summary":"The idea is to build PRAME-directed ImmTAC T-cell engagers for patients who carry HLA-A*24:02 or HLA-A*11:01 rather than HLA-A*02:01, the tissue type that tebentafusp and brenetafusp currently require. The antigen and format stay the same and only the HLA context changes, in principle a solved engineering problem; Immunocore and others already have preclinical ImmTACs against PRAME on HLA-A*24 and A*11, common in East Asian populations. The hypothesis is that these agents match the activity and safety of the A*02 drug, roughly doubling the number of people who could be treated. The test is a phase 1 dose escalation in HLA-A*24:02-positive melanoma in Japan and Korea mirroring IMCgp100-202; the evidence is preclinical and the idea bears on HLA-A*02:01 restriction.","asOf":"2026-09-07","links":[],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["t-cell-engager","tcr-t"],"targets":["prame"],"drugs":["brenetafusp","tebentafusp"],"companies":[],"institutions":[],"pathways":[],"terms":["hla-a02-restriction"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-imcgp100-202-n-engl-j-med-2021","paper-imcgp100-202-n-engl-j-med-2023-update","paper-tebentafusp-melanoma-cancers-basel-2019"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"PRAME-directed ImmTACs restricted to HLA-A*24:02 or A*11:01 achieve comparable activity and safety to the A*02 agent.","rationale":"Same antigen, same format; the only variable is the HLA context, which is a solved engineering problem in principle.","test":"Phase 1 dose escalation in HLA-A*24:02-positive melanoma in Japan and Korea, with ctDNA and OS follow-up mirroring IMCgp100-202.","maturity":"preclinical-evidence"},"route":"/ideas/idea-prame-tcr-beyond-a02/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"drug":[{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/"}],"term":[{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/"}],"paper":[{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/"},{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/"},{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/"}]}}